|
Daily Medical Update
Eczema & Atopic Dermatitis (Dupilumab, JAK inhibitors)
Sunday, March 15, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
1. Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis
Journal (2025) - Extension RCT
Key Findings
- Sustained control persisted up to 38 weeks after withdrawal in prior responders, with delayed flare recurrence versus historical expectations.
- Remission duration increased while rescue-treatment use decreased in maintained responders.
📋 Practice Implication: For stable responders, discuss step-down intervals with proactive relapse follow-up rather than indefinite unchanged dosing.
|
2. Deep response durability with lebrikizumab over 2 years in week-16 responders
Journal (2025) - Long-term extension
Key Findings
- Week-16 responders maintained high EASI improvement rates through 2 years versus baseline severity.
- Long-term deep response correlated with fewer flares and reduced topical corticosteroid exposure.
📋 Practice Implication: Early high responders may benefit from continuity strategies to preserve long-term disease suppression.
|
3. Biologics/JAK inhibitors and respiratory atopy outcomes in atopic dermatitis
Journal (2025) - Systematic Review
Key Findings
- Pooled evidence showed improved eczema outcomes without a clear increase in asthma/allergic-rhinitis exacerbation risk.
- Effect direction suggested stable-to-improved atopic comorbidity control as skin inflammation decreased.
📋 Practice Implication: Counsel multimorbid atopic patients that targeted AD escalation does not show a major respiratory harm signal in current evidence.
|
4. Upadacitinib efficacy/safety in moderate-to-severe atopic dermatitis
Journal (2024-2025) - Phase 3 RCT synthesis
Key Findings
- JAK1 therapy produced rapid itch reduction versus placebo, with clinically meaningful change often by week 1-2.
- Higher efficacy was accompanied by class-specific infection/laboratory monitoring requirements.
📋 Practice Implication: Prefer upadacitinib when rapid itch control is urgent, paired with structured CBC/LFT/lipid and infection surveillance.
|
5. Abrocitinib comparative outcomes in moderate-to-severe atopic dermatitis
Journal (2024-2025) - RCT/Meta-analysis
Key Findings
- Abrocitinib improved EASI and pruritus outcomes versus placebo across adult/adolescent cohorts.
- Benefit was offset by higher nausea/herpes-zoster signal in some datasets versus non-JAK comparators.
📋 Practice Implication: Use abrocitinib as an oral alternative for injection-averse patients, with pre-visit counseling on predictable adverse effects.
|
6. Dupilumab long-term effectiveness in real-world atopic dermatitis
Journal (2024-2025) - Cohort + Meta-analysis
Key Findings
- Long-term cohorts showed sustained control and steroid-sparing effects versus pre-biologic baseline disease activity.
- Conjunctivitis remained the most consistent non-serious adverse event requiring anticipatory management.
📋 Practice Implication: Keep dupilumab as first-line biologic referral option while adding routine ocular symptom checks during PCP follow-up.
|
|
Atopic dermatitis evidence this year supports earlier targeted-therapy escalation for uncontrolled moderate-to-severe disease, with meaningful differences between biologic and JAK options in response speed and monitoring burden.
|
|